Trodelvy is the first anti-Trop-2 ADC recently approved by the FDA for the treatment of adult patients with metastatic triple-negative breast cancer who have received at least two prior therapies for metastatic disease
Cell and gene therapies are revolutionizing the field of medicine by offering life-changing benefits to people with rare diseases and cancers
Manufacturers are increasingly being affected by the commercial insurance market’s shift of medical coverage policies to lower-cost alternate sites
UroGen has been preparing for the commercialization of Jelmyto by increasing customer awareness and discussing the high unmet need in low-grade UTUC
Dova recently entered into a merger agreement with Swedish Orphan Biovitrum AB (Sobi)
ncyte expects to add a significant boost to sales for the treatment of GVHD
OptumRx has been aggressively growing its portfolio of pharmacy care services businesses
EVERSANA, while being formed, realized that its customers needed patient-centered, value-based care